|
USP37 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.45560000017898E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.87079999999629E-05 |
| Normal-vs-Stage2 |
1.213880E-04 |
| Normal-vs-Stage3 |
2.38040000000161E-06 |
| Normal-vs-Stage4 |
2.12970000001977E-06 |
| Stage1-vs-Stage2 |
1.822830E-01 |
| Stage1-vs-Stage3 |
2.057400E-01 |
| Stage1-vs-Stage4 |
4.990400E-02 |
| Stage2-vs-Stage3 |
6.858600E-01 |
| Stage2-vs-Stage4 |
8.365800E-01 |
| Stage3-vs-Stage4 |
4.739800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.0954000000396E-06 |
| Normal-vs-AfricanAmerican |
1.285950E-01 |
| Normal-vs-Asian |
3.56460000000558E-05 |
| Caucasian-vs-AfricanAmerican |
1.355360E-01 |
| Caucasian-vs-Asian |
4.758400E-01 |
| AfricanAmerican-vs-Asian |
1.154160E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.60380000017113E-07 |
| Normal-vs-Female |
1.57516999998997E-05 |
| Male-vs-Female |
2.334200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.996500E-04 |
| Normal-vs-Age(41-60Yrs) |
9.80100000047557E-07 |
| Normal-vs-Age(61-80Yrs) |
1.74586999999171E-05 |
| Normal-vs-Age(81-100Yrs) |
2.763500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.577600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.258830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.211980E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.590200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.167400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.276600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.611600E-02 |
| Classical-VS-Follicular |
1.145620E-02 |
| Classical-VS-Other |
1.937440E-01 |
| Classical-VS-Normal |
1.385160E-04 |
| Tall-VS-Follicular |
9.255400E-01 |
| Tall-VS-Other |
6.854000E-01 |
| Tall-VS-Normal |
1.203490E-04 |
| Follicular-VS-Other |
6.820800E-01 |
| Follicular-VS-Normal |
2.00620000001539E-06 |
| Other-VS-Normal |
1.243560E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.40090000003246E-06 |
| Normal-vs-N1 |
1.67585999999442E-05 |
| N0-vs-N1 |
4.418800E-01 |
|
|
